FDA Approves Labcorp's Companion Diagnostic for Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio tissue complete CDx as a companion diagnostic. This approval helps identify patients with advanced melanoma who have specific BRAF variants, making them eligible for FDA-approved targeted therapies. This diagnostic aims to improve access to crucial treatments for patients with this aggressive form of skin cancer.